- Home
- SGA vs EPIX Comparison
SGA vs EPIX Comparison
Compare SGA & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- EPIX
- Stock Information
- Founded
- SGA 1986
- EPIX 2009
- Country
- SGA United States
- EPIX Canada
- Employees
- SGA N/A
- EPIX N/A
- Industry
- SGA Broadcasting
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- EPIX Health Care
- Exchange
- SGA Nasdaq
- EPIX Nasdaq
- Market Cap
- SGA 87.3M
- EPIX 75.9M
- IPO Year
- SGA 1992
- EPIX N/A
- Fundamental
- Price
- SGA $13.05
- EPIX $1.88
- Analyst Decision
- SGA
- EPIX Hold
- Analyst Count
- SGA 0
- EPIX 3
- Target Price
- SGA N/A
- EPIX $2.00
- AVG Volume (30 Days)
- SGA 6.7K
- EPIX 458.8K
- Earning Date
- SGA 08-07-2025
- EPIX 08-04-2025
- Dividend Yield
- SGA 7.66%
- EPIX N/A
- EPS Growth
- SGA N/A
- EPIX N/A
- EPS
- SGA 0.55
- EPIX N/A
- Revenue
- SGA $111,837,000.00
- EPIX N/A
- Revenue This Year
- SGA N/A
- EPIX N/A
- Revenue Next Year
- SGA $4.84
- EPIX N/A
- P/E Ratio
- SGA $23.89
- EPIX N/A
- Revenue Growth
- SGA N/A
- EPIX N/A
- 52 Week Low
- SGA $10.75
- EPIX $1.40
- 52 Week High
- SGA $16.48
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- SGA 49.58
- EPIX 65.24
- Support Level
- SGA $13.04
- EPIX $1.86
- Resistance Level
- SGA $13.65
- EPIX $1.88
- Average True Range (ATR)
- SGA 0.51
- EPIX 0.02
- MACD
- SGA -0.07
- EPIX 0.00
- Stochastic Oscillator
- SGA 27.95
- EPIX 100.00
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.